Description
An anti-inflammatory EPA metabolite; identified in mouse inflammatory exudates and in human plasma when subjects are treated with both aspirin and supplemental EPA; promotes inflammatory resolution in numerous disease models, including experimental colitis, asthma, atherosclerosis, type 2 diabetes, and HSV-1-induced stromal keratitis,
Formal name: 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid
Synonyms: RvE1
Molecular weight: 350.5
CAS: 552830-51-0
Purity: ≥95%
Formulation: A solution in ethanol
Product Type|Biochemicals|Lipids|Lipoxins/Resolvin Es||Research Area|Cardiovascular System|Cardiovascular Diseases|Atherosclerosis||Research Area|Immunology & Inflammation|Gastric Disease|Ulcerative Colitis||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Specialized Pro-Resolving Mediators||Research Area|Immunology & Inflammation|Pulmonary Diseases|Asthma||Research Area|Lipid Biochemistry|Cyclooxygenase Pathway||Research Area|Lipid Biochemistry|Cytochrome P450 Pathways||Research Area|Lipid Biochemistry|Lipoxygenase Pathways||Research Area|Neuroscience|Neurodegenerative Disorders|Alzheimer’s Disease